Put companies on watchlist
Novo Nordisk A/S
ISIN: US6701002056
WKN: 866931
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Novo Nordisk A/S · ISIN: US6701002056 · PR Newswire (ID: 20250806DC46076)
07 August 2025 12:40AM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO


NEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until September 30, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Novo Nordisk securities during the Class Period. A copy of the Complaint can be obtained awww.pomerantzlaw.com.

[Click here for information about joining the class action]

On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025, citing the impact of increased competition in the markets for its drugs Ozempic and Wegovy. 

 On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Danielle Peyton

Pomerantz LLP

dpeyton@pomlaw.com

646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-novo-nordisk-as-of-class-action-lawsuit-and-upcoming-deadlines---nvo-302523713.html

SOURCE Pomerantz LLP

Visual performance / price development - Novo Nordisk A/S
Smart analysis and research tools can be found here.
MIC: XNYS
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942